TendieTensor TendieTensor
You’re browsing as
Guest
Free Preview
Sign in/sign up to unlock all features.

News  ›  GlobeNewswire Inc.

ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE

GlobeNewswire Inc. Logo GlobeNewswire Inc. By Rosen Law Firm
ROSEN, A LEADING LAW FIRM, Encourages Skye Bioscience, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SKYE

Rosen Law Firm notifies Skye Bioscience investors of a securities class action lawsuit alleging false statements about the company's drug nimacimab and its clinical prospects, with a lead plaintiff deadline of January 16, 2026.

Insights
BAC   neutral

Mentioned as previous employer of new executive, with no direct commentary about the bank's performance


SKYE   negative

The lawsuit alleges the company made materially false and misleading statements about nimacimab's effectiveness, clinical prospects, and overall business operations, suggesting potential misconduct and investor harm